TransCode Therapeutics Implements 1-for-28 Reverse Stock Split to Maintain Nasdaq Compliance
TL;DR
TransCode Therapeutics (NASDAQ: RNAZ) implements 1-for-28 reverse stock split to raise per-share price, complying with Nasdaq's bid price requirement.
TransCode's reverse stock split reduces outstanding common stock to about 833,620 shares post-split for efficient trading and compliance with Nasdaq's rules.
TransCode's focus on developing RNA therapeutics to treat cancer aims to improve patient outcomes and contribute to the fight against metastatic disease.
The 1-for-28 reverse stock split by TransCode Therapeutics is a strategic move to reshape the company's stock structure and enhance market position.
Found this article helpful?
Share it with your network and spread the knowledge!
TransCode Therapeutics (NASDAQ: RNAZ) announced a 1-for-28 reverse stock split effective May 15, 2025, aimed at maintaining compliance with Nasdaq's minimum bid price requirements. The strategic financial maneuver will reduce the company's outstanding common stock from approximately 23.3 million to about 833,620 shares.
The reverse stock split, approved by shareholders and the board of directors, is designed to elevate the company's per-share price. Shareholders will see their existing shares consolidated, with no fractional shares issued; instead, amounts will be rounded up to the nearest whole share. Vstock Transfer LLC will serve as the exchange agent for this process.
This action is typical for early-stage biotechnology companies struggling to meet stock exchange listing standards. By reducing the number of outstanding shares, TransCode hopes to improve its stock's perceived value and maintain its Nasdaq listing, which is crucial for accessing capital markets and investor confidence.
Investors should note that while the total market capitalization remains unchanged, individual share prices will increase proportionally. The company will continue trading under its existing ticker, RNAZ, with a new CUSIP number of 89357L 501.
TransCode, a clinical-stage oncology company focusing on RNA therapeutics for metastatic disease, continues to develop innovative treatments targeting specific cancer biomarkers, including its lead candidate TTX-MC138.
Curated from InvestorBrandNetwork (IBN)
